Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2200]
News [4515]
Articles [113]
Editorials [23]
Conferences [175]
elearning [18]
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
PDL-1 assay concordance
Dr Jill Walker - AstraZeneca, UK
PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )
20 Oct 2016
Carcinoid syndrome
Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo...
Carcinoid syndrome ( Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )
12 Oct 2016
Who should receive combination therapy for ER positive breast cancer?
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Who should receive combination therapy for ER positive breast cancer? ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
12 Oct 2016
Drug repurposing of propranolol
Dr Pan Pantziarka - Anticancer Fund, UK
Drug repurposing of propranolol ( Dr Pan Pantziarka - Anticancer Fund, UK )
12 Oct 2016
Monitoring patterns of care in mCRPC patients with the help of the Cancer...
Dr Simon Chowdhury - Guy's Hospital, London, UK
Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Custirsen shows no survival benefit in metastatic prostate cancer
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
KRAS in the clinic and conference
Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI...
Dr Arndt Stahler - University of Munich, Munich, Germany
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation